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A B S T R A C T
Background
Loss-of-function variants in the gene encoding filaggrin (FLG) are major determinants of
eczema. We hypothesized that weakening of the physical barrier in FLG-deficient individuals
may potentiate the effect of environmental exposures. Therefore, we investigated whether
there is an interaction between FLG loss-of-function mutations with environmental exposures
(pets and dust mites) in relation to the development of eczema.
Methods and Findings
We used data obtained in early life in a high-risk birth cohort in Denmark and replicated the
findings in an unselected birth cohort in the United Kingdom. Primary outcome was age of
onset of eczema; environmental exposures included pet ownership and mite and pet allergen
levels. In Copenhagen (n¼379), FLG mutation increased the risk of eczema during the first year
of life (hazard ratio [HR] 2.26, 95% confidence interval [CI] 1.27–4.00, p¼ 0.005), with a further
increase in risk related to cat exposure at birth amongst children with FLG mutation (HR 11.11,
95% CI 3.79–32.60, p , 0.0001); dog exposure was moderately protective (HR 0.49, 95% CI
0.24–1.01, p¼ 0.05), but not related to FLG genotype. In Manchester (n¼ 503) an independent
and significant association of the development of eczema by age 12 mo with FLG genotype
was confirmed (HR 1.95, 95% CI 1.13–3.36, p¼ 0.02). In addition, the risk increased because of
the interaction of cat ownership at birth and FLG genotype (HR 3.82, 95% CI 1.35–10.81, p ¼
0.01), with no significant effect of the interaction with dog ownership (HR 0.59, 95% CI 0.16–
2.20, p ¼ 0.43). Mite-allergen had no effects in either cohort. The observed effects were
independent of sensitisation.
Conclusions
We have demonstrated a significant interaction between FLG loss-of-function main
mutations (501x and 2282del4) and cat ownership at birth on the development of early-life
eczema in two independent birth cohorts. Our data suggest that cat but not dog ownership
substantially increases the risk of eczema within the first year of life in children with FLG loss-of-
function variants, but not amongst those without. FLG-deficient individuals may need to avoid
cats but not dogs in early life.
The Editors’ Summary of this article follows the references.
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Introduction
We recently discovered in the Copenhagen Prospective
Study on Asthma in Childhood (COPSAC) that loss-of-
function variants in the gene encoding ﬁlaggrin (FLG) are
major determinants of eczema [1]. This ﬁnding has since been
replicated in other populations [2–4], and the population
attributable risk for eczema estimated at 11% [2].
FLG is situated in the Epidermal Differentiation Complex,
a dense cluster of genes on Chromosome 1q21. It codes for
the 500-kDa protein proﬁlaggrin, which is the main protein
component of the keratohyalin granules within the outermost
living cell layers of the epidermis. During terminal differ-
entiation of keratinocytes, proﬁlaggrin is dephosphorylated
into ﬁlaggrin peptides (37-kDa proteins), which form highly
compacted, chemically cross-linked layers that provide a
physical barrier that reduces water loss and protects the body
from potentially harmful environmental exposures. Non-
sense mutation R501X and frame-shift mutation 2282del4
lead to complete loss of ﬁlaggrin expression [5], which causes
excessively dry skin and impaired skin barrier function.
We hypothesized that weakening of skin barrier function in
ﬁlaggrin-deﬁcient individuals may modulate the effect of
environmental exposures, thus modifying the expression of
eczema. Since most eczema in individuals with FLG mutations
occurs within the ﬁrst year of life, the important environment
exposures that may affect the penetrance of FLG mutations
are likely to occur in the ﬁrst months of life. We therefore
investigated whether there is an interaction between FLG loss-
of-function mutations with early-life environmental expo-
sures (pets and dust mites) in relation to the development of
eczema. We used data obtained in a high-risk birth cohort in
Denmark, and in an unselected birth cohort in the UK.
Methods
COPSAC
COPSAC enrolled 411 high-risk neonates (mother with
veriﬁed asthma) at age 1 mo; the recruitment was previously
described in detail [6–8]. The study was approved by the
Ethics Committee for Copenhagen (KF 01–289/96) and The
Danish Data Protection Agency (2008-41-1754). Before enrol-
ment, informed consent was obtained from parents. Data
were collected on-line and locked after external monitoring.
An audit trail was run routinely.
Primary outcome. Eczema was diagnosed on clinical
examination in participants who were assessed at the
COPSAC Clinical Research Unit at age 1 mo, and at 6-mo
intervals thereafter; additional visits were arranged immedi-
ately upon the onset of any skin or respiratory symptoms.
Skin examinations, diagnoses, and treatment of eczema were
carried out by trained study physicians. Skin lesions were
described on-line according to predeﬁned morphology and
localization; eczema was deﬁned based on the Haniﬁn-Rajka
criteria as previously detailed [9,10].
Secondary outcome. Allergic sensitisation was deﬁned as
speciﬁc IgE . 0.35 kU/l to a range of common inhalant and
food allergens at age 6 and 18 mo (ImmunoCAP, Phadia) [11].
Environmental exposures. Pet exposure in early life was
determined at the interview at the 1-mo visit and deﬁned as
cat or dog living in the house at birth.
Allergen exposure was measured in the dust samples
collected from the child’s bed at age 1 y. Parents vacuumed
the bedding (the pillow and mattress) for 5 min with a dust
trap attached (ALK-Abello´). Mite, cat, and dog allergen
concentration was measured using the Sandwich ELISA [12].
Allergen exposure was dichotomized as high and low levels
(above and below the 75% quartile).
Charcoal cotton swabs were taken from the perineum of
the newborn and transported in Stuart transport media for
routine test for Staphylococcus aureus.
Manchester Asthma and Allergy Study
Manchester Asthma and Allergy Study (MAAS) is an
unselected population-based birth cohort described in detail
elsewhere [13,14]. The study is registered as ISRCTN72673620.
Participants were recruited prenatally, and followed prospec-
tively, attending the ﬁrst review clinic at ages 1, 3, and 5 y (6 4
wk). The study was approved by the Local Research Ethics
Committee (SOU/00/258; SOU/00/259). Written informed
consent was obtained from all parents.
Primary outcome. Information on the age of onset of
parentally reported eczema was collected by age 1 y using an
interviewer-administered validated International Study on
Asthma and Allergies in Childhood (ISAAC) questionnaire.
Secondary outcome. To assess allergic sensitisation chil-
dren were skin prick tested at age 1 y (dust mite, cat, dog,
grasses, milk, egg), and sensitisation was deﬁned as a weal
diameter 3 mm greater than the negative control.
Environmental exposures. Pet exposure in early life was
assessed by questionnaires administered during the home
visit carried out within 4 wk after birth and deﬁned as the
presence of a cat or a dog in the house at birth.
Allergen exposure was measured in dust samples collected
at age 1 y by vacuuming 1 m2 of living-room ﬂoor for 2 min.
Mite, cat, and dog allergen was quantitated using enzyme-
linked immunoassays; results were expressed as allergen
concentration (lg/g).
FLG Genotyping
Genotyping for R501X was performed using a TAQMAN-
based allelic discrimination assay (Applied Biosystems).
Allelic discrimination was assessed using Applied Biosystems
7700 sequence detection system. Probes and primers were as
described [1]. Mutation 2282del4 was genotyped by sizing of a
ﬂuorescent-labeled PCR fragment on an Applied Biosystems
3100 or 3730 DNA sequencer [1].
Statistical Analysis
Children were classiﬁed according to a two level dominant
genetic model (i.e., children were assigned as having a FLG
mutation if they were heterozygous or homozygous for the
null allele in at least one of the two SNPs).
Effects of environmental factors and their possible mod-
iﬁcation by genetic mutation were assessed by Kaplan-Meier
curves and Cox regression. The children were retained in the
analysis from birth until age at diagnosis of eczema, drop-out,
or age 1 y, whichever came ﬁrst. Simultaneous quantiﬁcation
of gene/environment effects was done by multiple Cox
regression. Pet exposure at birth and pet allergen exposure
were analysed separately. All analyses were carried out using
SAS 9.1.3, SPSS 13.0, and the free-ware statistical package R
(R Development Core Team, 2006). All estimates are reported
with 95% conﬁdence intervals [CI] in brackets.
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Results
The effects from FLG mutations in both cohorts occurred
early in life as demonstrated by the Kaplan Meier curves
(Figures 1 and 2), with hazard ratios (HR) of 2.90 (1.80–4.68)
and 2.06 (1.40–3.05) in the ﬁrst year and 0.71 (0.22–2.27) and
1.01 (0.48–2.51) after age 1 y (COPSAC and MAAS,
respectively). We therefore focused the analysis on the
interaction between FLG status and environmental exposures
during the ﬁrst year of life. Exposure variables in both
cohorts were independent of FLG mutations.
COPSAC
Of 411 infants, 379 of mixed European ancestry were
genotyped for 501x and 2282del4 [1] as well as R2448X and
S3247X [15]. The main mutated alleles 501x and 2282del4
were present in 40 children and exhibited a very strong
association to the development of eczema as previously
reported [1].
Eczema was diagnosed in 28% (105 children) before age 1 y;
265 (75%) did not have pets in their home at birth, 38 (11%)
had a cat, 37 (11%) had a dog, and 11 (3%) had both;
information on pet ownership was not available in 28
children. Among the 38 children with main mutations and
information on pet ownership, 26 (68%) did not have pets,
seven (18%) had a dog only, four (11%) had a cat only, and
one (3%) had both. Objective measure of allergen exposure
was available in 339 children; 205 (60%) had low cat and dog
allergen levels, 54 (16%) high cat allergen level, 54 (16%) high
dog allergen level, 26 (8%) high cat and dog allergen levels,
and 78 (23%) high mite allergen level. Among the 38 children
with mutation, 22 (58%) had low cat and dog allergen levels,
ﬁve (13%) high cat allergen level, nine (24%) high dog
allergen level, two (5%) had high cat and dog allergen levels,
and ten (26%) high mite allergen level. Six children were lost
to follow-up during the ﬁrst year but were included in the
analyses for the available follow-up period.
Kaplan-Meier plots suggested an increased risk of eczema
due to FLG mutation, and a further increased risk of eczema
due to cat exposure but only in the presence of FLG mutation
(Figure 3). Backwards elimination in a multiple Cox regres-
sion including FLG status, cat exposure, dog exposure, mite
allergen exposure, and interactions between FLG status and
cat exposure, dog exposure, and mite allergen exposure
showed a signiﬁcant interaction between cat exposure and
FLG status (p ¼ 0.0008) and a signiﬁcant effect of dog
exposure (p ¼ 0.05). An additional exploration of the cat
exposure-FLG status interaction demonstrated an increased
risk of developing eczema due to mutation (HR 2.26 [95% CI
1.27–4.00], p¼ 0.005), with an additional increased risk if also
exposed to cat (HR 11.11 [3.79–32.60], p , 0.0001). The
overall decrease in risk due to exposure to dog was quantiﬁed
in an HR of 0.49 [0.24–1.01]. Analysis including only children
carrying mutant alleles demonstrated a signiﬁcant effect of
cat ownership on development of eczema (HR 7.49 [2.37–
23.67], p ¼ 0.0006).
For allergen exposure a similar analysis was made with cat,
dog, and mite allergen levels. The model conﬁrmed an
increased risk of developing eczema due to mutation (HR
2.53 [1.45–4.41], p¼ 0.001) with an additional increase in risk
if exposed to high cat allergen level (HR 3.77 [1.45–9.81], p¼
0.006). In this analysis there was no signiﬁcant effect of dog or
mite allergens. Analysis including only children carrying
mutant alleles demonstrated a signiﬁcant effect of cat
allergen exposure on development of eczema (HR 3.09
[1.17–8.19], p ¼ 0.023).
Cat allergen exposure shows high agreement with reported
cat exposure at 4 wk (simple Kappa coefﬁcient 0.62 [0.51–
0.73]). Similarly dog allergen exposure shows high agreement
Figure 1. Kaplan-Meier Estimates of Cumulative Risk of Eczema in the
COPSAC Cohort with and without FLG Mutation
Numbers at risk at are given below the graph. Dashed line, no mutation;
solid line, mutation.
doi:10.1371/journal.pmed.0050131.g001
Figure 2. Kaplan-Meier Estimates of Cumulative Risk of Eczema in the
MAAS Cohort with and without FLG Mutation
Numbers at risk at are given below the graph. Dashed line, no mutation;
solid line, mutation.
doi:10.1371/journal.pmed.0050131.g002
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with reported dog exposure at 4 wk (simple Kappa coefﬁcient
0.59 [0.48–0.70]).
S. aureus was identiﬁed from the perineum in one newborn
before the age of 3 mo.
MAAS
Of 940 children with questionnaire data on the age of onset
of eczema, 513 provided a blood sample for DNA extraction.
Children who provided DNA did not differ from those who
did not in terms of family history, maternal age, socio-
economic status, history of eczema, allergic sensitisation, and
pet ownership (data available on request).
A total of 503 children of mixed European ancestry had
information on FLG main mutations (501x and 2282del4), pet
ownership at birth, and the age of onset of eczema. By age 1 y,
eczema was reported by 187/503 parents (37%). Mutated
alleles were present in 50 children (10%); 324 (64%) did not
own any pets at birth, 88 (18%) had a cat at home, 66 (13%)
had a dog, and 25 (5%) had both. The frequency of pet
ownership did not differ between children with or without
FLG mutation (no pets 293/453 [64.7%] and 31/50 [62%], cat
77/453 [17%] and 11/50 [22%], dog 60/453 [13.2%] and 6/50
[12%], and both cat and dog 23/453 [5.1%] and 2/50 [4%], no
FLG mutation versus FLG mutation, respectively, p ¼ 0.84).
Cat allergen exposure was available in 461 children, mite
allergen in 458, and dog allergen in 460.
Kaplan-Meier plots demonstrating the age of onset of
eczema in the ﬁrst year of life related to cat and dog
ownership amongst children with and without FLG mutation
are presented in Figure 4. The results of a multiple Cox
regression that included FLG genotype, cat and dog owner-
ship at birth, the interaction between FLG genotype with cat
and dog ownership, and mite exposure and its interaction
with FLG genotype indicated an increased risk of developing
eczema in the ﬁrst 12 mo due to FLG mutation (HR 1.95 [95%
CI 1.13–3.36], p¼ 0.017). Furthermore, in the presence of FLG
mutation, the risk increased further because of cat ownership
at birth, with no signiﬁcant effect of cat ownership being
observed amongst children without FLG mutation (interac-
tion of cat ownership at birth and FLG mutation, HR 3.82
[1.35–10.81], p¼ 0.011). There was a trend for dog ownership
to increase the risk (HR 1.51 [0.96–2.37], p ¼ 0.075), with no
signiﬁcant interaction of FLG genotype with dog ownership
(HR 0.59 [0.16-2.20], p ¼ 0.43) or mite allergen exposure (HR
1.15 [0.93–1.43], p ¼ 0.21). There was no signiﬁcant effect of
having both cats and dogs (HR 1.57 [0.82–3.03]), or their
interaction with FLG genotype (p ¼ 0.96). Analysis including
only children carrying mutant alleles demonstrated a
signiﬁcant effect of cat ownership on development of eczema
(HR 2.47 [1.09–5.62], p ¼ 0.03).
In terms of allergen exposure there was no signiﬁcant
correlation between mite, cat, and dog allergen levels.
Multiple Cox regression that included FLG genotype, cat,
dog, and mite allergen levels, and the interaction between
genotype and allergen levels conﬁrmed an increased risk of
developing eczema due to mutation (HR 2.22 [1.27–3.89], p¼
0.005) and the interaction between cat allergen and FLG
genotype (with risk increasing risk with increasing allergen
level among children with FLG mutation; HR for interaction
1.31 [1.03–1.67], p ¼ 0.026). Nonsigniﬁcant trends were
Figure 3. COPSAC: Kaplan-Meier Estimates of Cumulative Risk of Eczema during the First Year of Life Stratified on Mutation and Cat at Birth Status
Numbers at risk at birth, 6, and 12 mo are given below the graph.
Dashed line, no cat at birth; solid line, cat at birth.
doi:10.1371/journal.pmed.0050131.g003
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observed for dog allergen exposure (HR 1.07 [1.00–1.15], p ¼
0.06), the direction of which appeared to inverse in the
interaction with FLG mutation (0.84 [0.68–1.05, p ¼ 0.1]).
Secondary outcomes. Allergic sensitisation was uncommon
in early life in both cohorts (in COPSAC, cat sensitisation was
detected in one infant with FLG mutation at 6 mo but none at
18 mo; in MAAS, two children were skin test positive to mite,
four to cat, and three to dog at age 1 y). We therefore did not
analyse sensitisation further.
Discussion
Principal Findings
We have demonstrated a signiﬁcant interaction between
FLG loss-of-function main mutations (501x and 2282del4) and
cat ownership at birth on the development of early-life
eczema in two independent birth cohorts. Our data suggest
that cat but not dog ownership substantially increases the risk
of eczema within the ﬁrst year of life in children with FLG
loss-of-function variants, but not amongst those without. The
observed effects were independent of allergic sensitisation.
For the primary outcome we selected age of onset of early
eczema. The rationale for this is that in both cohorts the
increased risk of eczema amongst FLG mutation carriers
occurred only in the ﬁrst year of life and not thereafter
(Figures 1 and 2). Therefore development of eczema during
the ﬁrst year of life is the relevant outcome when studying
this gene-environment interaction. This also means that the
important environmental exposures that may interact with
FLG in the development of eczema must occur in the ﬁrst
months of life. This limits the number of relevant exposures,
as neonates typically live in a very sheltered environment.
Limitations and Strengths
This was a hypothesis-driven analysis. We hypothesized that
weakening of physical barrier of skin in FLG deﬁcient
individuals may potentiate the effect of relevant environ-
mental exposures. Therefore we investigated whether there is
an interaction between FLG loss-of-function mutations with a
range of environmental exposures for which the skin could be
the relevant route of exposure. Since FLG is not expressed in
either lungs or GI tract, we did not test exposures through
such routes. We focused on the exposure that was associated
with eczema in previous epidemiological studies and that was
common for the two populations tested (domestic pets and
indoor allergens). In addition, in COPSAC we explored the
possibility of testing the effect of skin colonization with S.
aureus, but only one child in the mutated group was colonized
on the skin.
The different designs of the two cohorts prevented data
pooling in favour of replication, and necessitated some
differences in data analysis. Clinical outcomes were not
identical, resulting in a higher prevalence of infant eczema in
MAAS (parentally reported, 37%) compared to COPSAC
(investigator-diagnosed, 28%). This suggests that MAAS was
capturing milder cases and overreporting of eczema by
parents. COPSAC provided closely monitored prospective
data on eczema progression. The speciﬁcity of diagnosis was
high, since the detailed phenotyping and management was
carried out solely by the investigators, reducing the risk of
misclassiﬁcation [9], which is of particular importance in the
clinical evaluation of eczema where interobserver variation is
a problem [16]. Despite the differences in deﬁnition of
primary outcome, we achieved replication.
We acknowledge the fact that the initial ﬁnding is based on
Figure 4. MAAS: Kaplan-Meier Estimates of Cumulative Risk of Eczema during the First Year of Life Stratified on Mutation and Cat at Birth Status
Numbers at risk at birth, 6, and 12 mo are given below the graph.
Dashed line, no cat at birth; solid line, cat at birth.
doi:10.1371/journal.pmed.0050131.g004
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only ﬁve children with eczema with a cat at home and
carrying FLG mutation in COPSAC, but the power of the
statistics (p , 0.0001) derives from the longitudinal dataset
with the time of onset clearly distinguishing these popula-
tions. Cross-sectional analyses would not have such statistical
power. Furthermore, it is worth noting that the ﬁndings were
conﬁrmed in the analysis of allergen levels, that pet owner-
ship did not differ between those with and without the
variant, and that the interaction between FLG variants and
cat ownership was replicated in an independent cohort that
included a larger number of cat exposed FLG mutation
carriers.
Allergens levels were measured at age 1 y representing
allergen exposure during the ﬁrst year of life. Dust samples
were taken from the child’s mattress in COPSAC and from
the lounge ﬂoor in MAAS, which resulted in different
distribution of results (10-fold increase from third to fourth
quartile in COPSAC with only 3-fold difference in MAAS,
indicating that quartile analysis would not be appropriate in
MAAS). Although we used different indices of allergen
exposure, we obtained similar results.
In the original discovery in COPSAC of the loss-of-function
variants 501x and 2282del4 in the gene encoding ﬁlaggrin, we
demonstrated a strong association to the development of
eczema in the ﬁrst years of life. Two new SNPs within the
ﬁlaggrin gene (R2447X and S3247X) have since been reported
[15] and were found in eight children in COPSAC. However,
these new SNPs are qualitatively different from the old
mutations with some residual function as demonstrated by a
signiﬁcantly lower penetrance of eczema. Inclusion of the
novel SNPs would therefore weaken our analyses by mixing a
well-known strong risk factor with a weak risk factor, which
furthermore is qualitatively different and therefore may have
a different effect on the gene–environmental interactions
studied. As a consequence we did not ﬁnd it reasonable to
formulate a dominant genetic model based on all four SNPs.
Meaning of the Study
Several studies have suggested an effect of early-life pet
exposure on the development of atopic disease. However, the
data are inconsistent, with some studies showing increased
risk [17], and others decreased risk [18], or no effect [19].
These inconsistencies may be due in part to epidemiological
artifacts. Recall bias is an obvious risk when exposure
assessments are retrospective. Selection for keeping pets is
another potential bias. The time from exposure to assessment
of the health outcome has been long in some studies, which
may lead to confounding by early modiﬁcation of the
exposure and therefore affect the long-term outcome. The
causal-effect direction may be uncertain in retrospective
assessments, as the pets may have been acquired after the
disease onset. Furthermore, cross-sectional studies may
report protective effects from pet exposure, when in fact
individuals have removed the pet from the household because
of the disease or the factors associated with a predisposition
to disease. Importantly, in both our studies we documented
pet exposure at birth (i.e., before eczema occurrence), thus
eliminating uncertainty of the direction of association
between exposure and disease. The ﬁndings were further
supported by objective measures of allergen exposure.
We only assessed animals living in the household, though
other exposures outside the home may be relevant, but this
would only have biased the risk estimates toward the null,
potentially underestimating the true risk. Having pets has
been reported to be biased from socioeconomic status,
smoking habits, and parental allergic rhinitis [20], but it is
unlikely to affect the genetic distribution in the study
population and could therefore not act as confounder.
The mechanism by which cat exposure drives the develop-
ment of eczema is unknown. Our data suggest that it does not
act through cat-speciﬁc immunoglobulin E (IgE). This is in
keeping with previous studies showing that the effect of FLG
loss-of-function mutations was equally strong on allergic and
nonallergic eczema, demonstrating that the development of
eczema is not dependent on allergic sensitisation [2]. Cat
exposure may act through other nonallergic mechanisms
such as endotoxins. COPSAC recently reported that bacterial
colonization of the airways in neonates was associated with
later development of recurrent wheeze, asthma, and in-
creased total immunoglobulin E (IgE) [8]. It may be possible
that cat exposure mediates its effect in the FLG mutated
genotypes via altered bacterial exposure, or that cat exposure
may be a surrogate marker for other unknown environmental
inﬂuences penetrating the imperfect skin barrier because of
defective proﬁlaggrin synthesis.
Conclusions
Although there are many new susceptibility genes for
complex disorders following genome-wide association stud-
ies, there are very few gene–environment studies. Our
ﬁndings of a consistent effect from early-life cat ownership
on the phenotypic expression of eczema in infants with FLG
loss-of-function mutations in two independent birth cohorts
is an example of gene–environment interaction in a common
complex disease, demonstrating that such gene–environment
interactions exist and are detectable given appropriately
detailed studies of environmental exposures.
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Editors’ Summary
Background. Eczema is a skin condition characterized by dry, red, and
itchy patches on the skin. Eczema is associated with asthma and allergy,
though allergy rarely plays a role in development or severity of eczema.
Eczema usually begins during infancy, typically on the face, scalp, neck,
extensor sides of the forearms, and legs. Up to one in five infants
develops eczema, but in more than half of them, the condition improves
or disappears completely before they are 15 years old. If eczema persists
into adulthood, it usually affects the face and the skin inside the knees
and elbows. There is no cure for eczema but it can be controlled by
avoiding anything that makes its symptoms worse. These triggers
include irritants such as wool, strong soaps, perfumes, and dry
environments. A good skin-care routine and frequent moisturizing can
also help to keep eczema under control, but in many cases, cortico-
steroid creams and ointments may be necessary to reduce inflammation.
Why Was This Study Done? Eczema tends to run in families. This
suggests that eczema is caused by genetic factors as well as by
environmental factors. Recently, researchers discovered that two
common ‘‘loss-of-function’’ variants in the gene encoding filaggrin
(FLG) predispose people to eczema. People who inherit one or two
defective genes make no filaggrin, a protein that normally forms a
physical barrier in the skin that protects the body from potentially
harmful substances in the environment. Might the weakening of this
barrier in filaggrin-deficient individuals affect their responses to environ-
mental substances to which the skin is exposed? In this study, the
researchers test this potential explanation for how genetic and environ-
mental factors (in particular, exposure to pets) might interact to
determine an individual’s chances of developing eczema.
What Did the Researchers Do and Find? To test their hypothesis, the
researchers studied two independent groups of infants during their first
year of life—a high-risk group consisting of infants born in Copenhagen,
Denmark to mothers with asthma and a group of infants born to women
from the general population in Manchester, United Kingdom. The
researchers determined which FLG variants each child had inherited and
classified those with either one or two defective copies of FLG as having
an FLG mutation. They determined pet exposure in early life by asking
whether a dog or a cat was living in the parental home when the child
was born (‘‘pet ownership’’) and then analyzed how these genetic and
environmental factors affected the age of onset of eczema. In both
groups, children with FLG mutations were twice as likely to develop
eczema during the first year of life as children without FLG mutations. For
children without FLG mutations, cat ownership at birth had no effect on
eczema risk but for children with FLG mutations, cat ownership at birth
(but not dog ownership) further increased the risk of developing eczema.
What Do These Findings Mean? These findings show that FLG
mutations and cat ownership at birth interact to determine the chances
of a child developing eczema during the first year of life. They provide
support, therefore, for the researchers’ suggestion that the weakening of
the skin’s protective barrier that is caused by filaggrin deficiency
increases the child’s susceptibility to factors associated with cat
exposure. Only a small number of children in this study carried FLG
mutations and were exposed to cats from birth, so these findings need
confirming in independent studies. In addition, it is still not clear how
exposure to cats drives the development of eczema. Allergy was not the
mechanism as the FLG-deficient children exposed to cat and who
developed eczema did not develop cat-specific immunoglobin E
antibodies. Nevertheless, these findings suggest that, to reduce their
risk of developing eczema, filaggrin-deficient individuals should avoid
cats (but not dogs) during the first few months of life.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0050131.
 The MedlinePlus Encyclopedia has a page on eczema (in English and
Spanish); links to further information are provided by MedlinePlus
 EczemaNet is a comprehensive online information resource about
eczema provided by the American Academy of Dermatologists
 The US National Institute of Arthritis and Musculoskeletal and Skin
Diseases provides information on eczema
 The UK National Health Service Direct health encyclopedia provides
information for patients on eczema (in several languages)
 The Copenhagen Studies on Asthma in Childhood (COPSAC) and
Manchester Asthma and Allergy Study (MAAS) Web sites provide more
information about the children involved in this research
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